T7402

Paclitaxel

from Taxus brevifolia, ≥95% (HPLC), powder

• Fórmula empírica (notación de Hill): C₄₇H₅₁NO₁₄
• Número de CAS: 33069-62-4
• Peso molecular: 853.91
• Beilstein/REAXYS Number: 1420457
• MDL number: MFCD00869953
• UNSPSC Code: 12161501
• PubChem Substance ID: 24277878
• NACRES: NA.77

Propiedades

• biological source: Taxus brevifolia
• assay: ≥95% (HPLC)
• form: powder
• color: white
• mp: 213 °C (dec.) (lit.)
• solubility: DMSO: 50 mg/mL (can be stored frozen for several months); methanol: soluble 50 mg/mL, clear, colorless (undergoes transesterification); ethanol: soluble
• antibiotic activity spectrum: viruses
• mode of action: DNA synthesis | interferes
• originator: Bristol-Myers Squibb
• storage temp.: 2-8°C
• SMILES string: [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7
• InChI: 1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
• InChI key: RCINICONZNJXQF-MZXODVADSA-N
• Gene Information: human ... BCL2(596) , TUBA1A(7846) , TUBA1B(10376) , TUBA1C(84790) , TUBA3C(7278) , TUBA3E(112714) , TUBA4A(7277) , TUBB(203068) , TUBB1(81027) , TUBB2A(7280) , TUBB2B(347733) , TUBB3(10381) , TUBB4A(10382) , TUBB4B(10383) , TUBB6(84617) , TUBB8(347688)

Descripción

General description

Chemical structure: taxoide

Application

Paclitaxel has been used as a component of the dechorionation buffer for Gryllus bimaculatus eggs. Paclitaxel has also been used for studying its effect on the movement of all-trans retinoic acid (ATRA) differentiated NB4 cells.

Biochem/physiol Actions

Paclitaxel is a potent anti-neoplastic and anti-mitotic taxane drug, which binds to the N-terminus of β-tubulin and and stabilizes microtubules arresting the cell cycle at the G2/M phase. The microtubule damage induces apoptosis through a JNK-dependent pathway followed by a JNK-independent pathway, perhaps related to the activation of protein kinase A (PKA) or of Raf-1 kinase, resulting in phosphorylation of Bcl-2. A major metabolite via CYP2CB is 6α-hydroxypaclitaxel (6α-OHP).

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Caution

Paclitaxel undergoes transesterification in methanol and hydrolyzes in aqueous solutions.

Preparation Note

Paclitaxel is soluble in methanol at 50 mg/ml and yields a clear, colorless solution. It is also soluble in DMSO (50 mg/ml) and ethanol.

Información de seguridad

• pictograms: GHS08
• signalword: Danger
• hcodes: H341,H360FD,H371,H372
• pcodes: P202 - P260 - P264 - P280 - P308 + P311 - P405
• Hazard Classifications: Muta. 2 - Repr. 1B - STOT RE 1 - STOT SE 2
• target_organs: Central nervous system,Bone marrow,Cardio-vascular system, Eyes,Central nervous system
• Storage Class: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges